PTC124 Featured At Third Annual Congress Of Myology - PTC Announces Initiation Of Additional Phase 2b Clinical Trial Sites In Europe

PTC Therapeutics, Inc. (PTC) announced that PTC124, the company’s orally delivered investigational new drug for the treatment of genetic disorders due to nonsense mutations, was featured in a symposium at Myology 2008, the Third Annual Congress of Myology, on Friday, May 30 in Marseilles.

More: continued here

Filed under: Muscular Dystrophy on June 10th, 2008